Board to review Q2 and half-year results on November 5

Results View source PDF Explain this filing

IPCALAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.1%Reaction day

₹1921.00

prior close

₹1931.80

announcement price

In-mkt

timing

Nifty Midcap 150market-0.8%-0.3% vs market

Pharmaceuticals peers, median of 170sector-0.5%-0.6% vs sector

On the reaction day the stock moved 0.3 pts less than Nifty Midcap 150 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.2

15m

-0.5

30m

-0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.1-0.8-0.3-0.5-0.6

Next day

+1.0-2.9+3.9-2.2+3.2

+0.6-1.8+2.4-1.1+1.6

+3.2-0.9+4.2+0.7+2.6

+0.2pendingpending+1.9-1.7

—————

15d

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Ipca Laboratories will hold a board meeting on November 5, 2026, to approve standalone and consolidated unaudited results for the quarter and six months ended September 30, 2026. Insider trading remains closed from October 1 until 48 hours after the results are declared.

Likely market impact

No earnings figures are provided. Shareholder focus will shift to the November 5 results and any changes in profit, revenue, margins, or cash flow.